Black Hawk Acquisition closed at $4.50 on Nov 5, down 19.21%, 65.6% below its highest close since May 13. Volume of 7.2K shares was 0.12× its 20-day average (below normal).
Split-adjusted performance: -65.4% over one month.
Short interest was 103.2K shares at the Oct 15 settlement, up 20501.6% from the prior report (2.6% of float, 2.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BKHABlack Hawk Acquisition | $4.50 | −19.21% | — | — | — | — | $18.7M | |
| BSEMBioStem Technologies | $1.04 | −9.57% | — | — | — | — | $19.4M | Compare |
| ESLAEstrella Immunopharma | $0.4101 | −7.53% | −67.7% | — | — | — | $17.8M | Compare |
| PLURPluri | $1.19 | −3.26% | −64.4% | −15.8% | −1755.2% | — | $16.1M | Compare |
| JSPRJasper Therapeutics | $0.4692 | −8.20% | −48.3% | — | — | — | $15.6M | Compare |
| ABOSAcumen Pharmaceuticals | $0.2138 | −1.16% | −91.3% | — | — | — | $15.5M | Compare |
| ATYRaTyr Pharma | $6.03 | −2.43% | −83.6% | — | — | — | $15.1M | Compare |
| CVMCel-Sci | $1.37 | −0.72% | −14.4% | — | — | — | $24.1M | Compare |
| DYAIDyadic International | $0.3401 | −7.25% | −54.3% | −0.6% | −221.0% | — | $13.6M | Compare |
No recent articles focused on Black Hawk Acquisition. 1 articles mention it in passing.
Black Hawk Acquisition Corp is a Blank check company.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology